Skip to content

DocGo DCGO Net additions (releases) charged to costs and expenses

Net additions (releases) charged to costs and expenses at other companies

InfuSystem Holdings logo
InfuSystem HoldingsINFU
Medline, Inc.
 logo
Medline, Inc. MDLN

Other financials

Income statement

See full
Revenue$75.6M-21.3%
Gross profit-$407.9M-25.6%
Operating income-$18.7M-33.7%
Net income-$14.8M-57.0%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$46.8M-54.6%
Total debt$28.5M-7.6%
Total equity$132.3M-57.2%
Total assets$209.2M-51.4%

Cash flow

See full
Operating cash flow-$4.7M-151%
CapEx$430.3K-58.2%
Free cash flow-$5.1M-162%

Valuation

See full
Market cap$50.98M-67.2%
Enterprise value$32.67M-59.1%
P/S0.2×-0.2×

Profitability

See full
Operating margin-60.6%
Net margin-62.2%
FCF margin14.6%+8.1pp

Returns & leverage

See full
Return on equity-85%
Debt / equity0.2×+0.1×
Current ratio1.8×-0.7×

Where this comes from

Reported directly by DocGo in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: DocGo’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about DocGo's net additions (releases) charged to costs and expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DocGo's net additions (releases) charged to costs and expenses?
DocGo (DCGO) reported net additions (releases) charged to costs and expenses of $1.73M in Q1 2026.
How has DocGo's net additions (releases) charged to costs and expenses changed year-over-year?
DocGo's net additions (releases) charged to costs and expenses increased by 38.9% year-over-year, from $1.25M to $1.73M.
What is the long-term trend for DocGo's net additions (releases) charged to costs and expenses?
Over 4 years (2021 to 2025), DocGo's net additions (releases) charged to costs and expenses has grown at a 28.1% compound annual growth rate (CAGR), from $4.47M to $12.05M.